The complex interplay of tumor-infiltrating cells in driving therapeutic resistance pathways

被引:6
作者
Li, Dengxiong [1 ]
Shao, Fanglin [2 ]
Yu, Qingxin [3 ,11 ]
Wu, Ruicheng [1 ]
Tuo, Zhouting [4 ]
Wang, Jie [1 ]
Ye, Luxia [5 ]
Guo, Yiqing [5 ]
Yoo, Koo Han [6 ]
Ke, Mang [5 ,12 ]
Okoli, Uzoamaka Adaobi [7 ,8 ]
Premkamon, Chaipanichkul [7 ]
Yang, Yubo [9 ]
Wei, Wuran [1 ]
Heavey, Susan [7 ]
Cho, William C. [10 ]
Feng, Dechao [1 ,7 ]
机构
[1] Sichuan Univ, West China Hosp, Inst Urol, Dept Urol, Chengdu 610041, Peoples R China
[2] Southwest Med Univ, Affiliated Hosp, Dept Rehabil, Luzhou 646000, Peoples R China
[3] Ningbo Clin Pathol Diag Ctr, Dept Pathol, Ningbo 315211, Peoples R China
[4] Anhui Med Univ, Affiliated Hosp 2, Dept Urol, Hefei 230601, Peoples R China
[5] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Publ Res Platform, Linhai 317000, Peoples R China
[6] Kyung Hee Univ, Dept Urol, Seoul, South Korea
[7] UCL, Div Surg & Intervent Sci, London W1W 7TS, England
[8] Univ Nigeria, Coll Med, Dept Pharmacol & Therapeut, Basic & Translat Canc Res Grp, Nsukka, Enugu State, Nigeria
[9] Chongqing Univ, Three Gorges Hosp, Dept Urol, Chongqing 404000, Peoples R China
[10] Queen Elizabeth Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[11] Lihuili Hosp, Ningbo Med Ctr, Dept Pathol, Ningbo, Peoples R China
[12] Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Urol, Taizhou, Peoples R China
关键词
Tumor microenvironment; Infiltrated cells; Drug resistance; Immunotherapy; Targeted therapy; Radiotherapy; CANCER-CELLS; FIBROBLASTS; INHIBITION; RADIORESISTANCE; CHEMORESISTANCE; CONTRIBUTES; MACROPHAGES; METABOLISM; ACTIVATION; PD-L1;
D O I
10.1186/s12964-024-01776-7
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Drug resistance remains a significant challenge in cancer treatment. Recently, the interactions among various cell types within the tumor microenvironment (TME) have deepened our understanding of the mechanisms behind treatment resistance. Therefore, this review aims to synthesize current research focusing on infiltrating cells and drug resistance suggesting that targeting the TME could be a viable strategy to combat this issue. Numerous factors, including inflammation, metabolism, senescence, hypoxia, and angiogenesis, contribute to drug resistance could be a viable strategy to combat this issue. Overexpression of STAT3 is commonly associated with drug-resistant cancer cells or stromal cells. Current research often generalizes the impact of stromal cells on resistance, lacking specificity and statistical robustness. Thus, future research should take notice of this issue and aim to provide high-quality evidence. Despite the existing limitations, targeting the TME to overcome therapy resistance hold promising and valuable potential.
引用
收藏
页数:17
相关论文
共 166 条
  • [1] Ahmed Shaza, 1868, BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, V2021, DOI [10.1016/j.bbamcr, DOI 10.1016/J.BBAMCR]
  • [2] Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2
    Alicea, Gretchen M.
    Rebecca, Vito W.
    Goldman, Aaron R.
    Fane, Mitchell E.
    Douglass, Stephen M.
    Behera, Reeti
    Webster, Marie R.
    Kugel, Curtis H., III
    Ecker, Brett L.
    Caino, M. Cecilia
    Kossenkov, Andrew, V
    Tang, Hsin-Yao
    Frederick, Dennie T.
    Flaherty, Keith T.
    Xu, Xiaowei
    Liu, Qin
    Gabrilovich, Dmitry, I
    Herlyn, Meenhard
    Blair, Ian A.
    Schug, Zachary T.
    Speicher, David W.
    Weeraratna, Ashani T.
    [J]. CANCER DISCOVERY, 2020, 10 (09) : 1282 - 1295
  • [3] Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells
    Ames, Erik
    Canter, Robert J.
    Grossenbacher, Steven K.
    Mac, Stephanie
    Smith, Rachel C.
    Monjazeb, Arta M.
    Chen, Mingyi
    Murphy, William J.
    [J]. ONCOIMMUNOLOGY, 2015, 4 (09): : 1 - 11
  • [4] Cancer associated fibroblasts induce proliferation and therapeutic resistance to everolimus in neuroendocrine tumors through STAT3 activation
    Amin, Tania
    Viol, Fabrice
    Krause, Jenny
    Fahl, Martina
    Eggers, Corinna
    Awwad, Fayez
    Schmidt, Benjamin
    Benten, Daniel
    Ungefroren, Hendrik
    Fraune, Christoph
    Clauditz, Till S.
    Sauter, Guido
    Izbicki, Jakob R.
    Lohse, Ansgar W.
    Huber, Samuel
    Schrader, Joerg
    [J]. NEUROENDOCRINOLOGY, 2023, 113 (05) : 501 - 518
  • [5] GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy
    Ancey, Pierre-Benoit
    Contat, Caroline
    Boivin, Gael
    Sabatino, Silvia
    Pascual, Justine
    Zangger, Nadine
    Perentes, Jean Yannis
    Peters, Solange
    Abel, E. Dale
    Kirsch, David G.
    Rathmell, Jeffrey C.
    Vozenin, Marie-Catherine
    Meylan, Etienne
    [J]. CANCER RESEARCH, 2021, 81 (09) : 2345 - 2357
  • [6] Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
    Aslan, Katrin
    Turco, Verena
    Blobner, Jens
    Sonner, Jana K.
    Liuzzi, Anna Rita
    Nunez, Nicolas Gonzalo
    De Feo, Donatella
    Kickingereder, Philipp
    Fischer, Manuel
    Green, Ed
    Sadik, Ahmed
    Friedrich, Mirco
    Sanghvi, Khwab
    Kilian, Michael
    Cichon, Frederik
    Wolf, Lara
    Jaehne, Kristine
    von Landenberg, Anna
    Bunse, Lukas
    Sahm, Felix
    Schrimpf, Daniel
    Meyer, Jochen
    Alexander, Allen
    Brugnara, Gianluca
    Roeth, Ralph
    Pfleiderer, Kira
    Niesler, Beate
    von Deimling, Andreas
    Opitz, Christiane
    Breckwoldt, Michael O.
    Heiland, Sabine
    Bendszus, Martin
    Wick, Wolfgang
    Becher, Burkhard
    Platten, Michael
    [J]. NATURE COMMUNICATIONS, 2020, 11 (01)
  • [7] Article Long-lasting mRNA-encoded interleukin-2 restores CD8+T cell neoantigen immunity in MHC class I-deficient cancers
    Beck, Jan D.
    Diken, Mustafa
    Suchan, Martin
    Streuber, Michael
    Diken, Elif
    Kolb, Laura
    Allnoch, Lisa
    Vascotto, Fulvia
    Peters, Daniel
    Beissert, Tim
    Akilli-Oeztuerk, Oezlem
    Tuereci, Oezlem
    Kreiter, Sebastian
    Vormehr, Mathias
    Sahin, Ugur
    [J]. CANCER CELL, 2024, 42 (04) : 568 - 582.e11
  • [8] Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
    Benguigui, Madeleine
    Vorontsova, Avital
    Timaner, Michael
    Levin, Sapir
    Haj-Shomaly, Jozafina
    Deo, Abhilash
    Menachem, Rotem
    Manobla, Bar
    Cooper, Tim J.
    Raviv, Ziv
    Shaked, Yuval
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Targeting TREM2 on tumor-associated macrophages enhances immunotherapy
    Binnewies, Mikhail
    Pollack, Joshua L.
    Rudolph, Joshua
    Dash, Subhadra
    Abushawish, Marwan
    Lee, Tian
    Jahchan, Nadine S.
    Canaday, Pamela
    Lu, Erick
    Norng, Manith
    Mankikar, Shilpa
    Liu, Victoria M.
    Du, Xiaoyan
    Chen, Amanda
    Mehta, Ranna
    Palmer, Rachael
    Juric, Vladislava
    Liang, Linda
    Baker, Kevin P.
    Reyno, Leonard
    Krummel, Matthew F.
    Streuli, Michel
    Sriram, Venkataraman
    [J]. CELL REPORTS, 2021, 37 (03):
  • [10] HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
    Bourbon, Estelle
    Sesques, Pierre
    Gossez, Morgane
    Tordo, Jeremie
    Ferrant, Emmanuelle
    Safar, Violaine
    Wallet, Florent
    Aussedat, Guillaume
    Maarek, Alizee
    Boua, Fadhela
    Karlin, Lionel
    Ghergus, Dana
    Golfier, Camille
    Lequeu, Helene
    Lazareth, Anne
    Schwiertz, Verane
    Viel, Sebastien
    Idlhaj, Maryam
    Ghesquieres, Herve
    Monneret, Guillaume
    Bachy, Emmanuel
    Venet, Fabienne
    [J]. BLOOD ADVANCES, 2023, 7 (05) : 744 - 755